GlaxoSmithKline's new boss streamlines drug research
[LONDON] GlaxoSmithKline's new chief executive Emma Walmsley announced plans on Wednesday to streamline drug research in a bid to improve returns in the group's core pharmaceuticals business.
Ms Walmsley, who took over in April, said GSK would allocate capital to priority areas including respiratory and HIV and infectious diseases, and two potential areas of oncology and immuno-inflammation. More than 30 pre-clinical and clinical programmes will be stopped.
The announcement came as Britain's biggest drugmaker reported a 12 per cent rise in adjusted earnings per share in sterling terms to 27.2 pence on sales up 12 per cent at £7.32 billion (S$12.97 billion). Analysts, on average, had forecast sales of £7.26 billion and EPS of 26.2 pence, according to Thomson Reuters data.
REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cordlife requests trading halt after dropping 15.2% to all-time low, pending announcement
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain